The HBV drug entecavir - Effects on HIV-1 replication and resistance

Moira A. McMahon, Benjamin L. Jilek, Timothy P. Brennan, Lin Shen, Yan Zhou, Megan Wind-Rotolo, Sifei Xing, Shridhar Bhat, Braden Hale, Robert Hegarty, Curtis R. Chong, Jun Liu, Robert F Siliciano, Chloe L Thio

Research output: Contribution to journalArticle

Abstract

Entecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus type 1 (HIV-1) at clinically relevant doses. We observed that entecavir led to a consistent 1-log 10 decrease in HIV-1 RNA in three persons with HIV-1 and HBV coinfection, and we obtained supportive in vitro evidence that entecavir is a potent partial inhibitor of HIV-1 replication. Detailed analysis showed that in one of these patients, entecavir monotherapy led to an accumulation of HIV-1 variants with the lamivudine-resistant mutation, M184V. In vitro experiments showed that M184V confers resistance to entecavir. Until more is known about HIV-1-resistance patterns and their selection by entecavir, caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who are not receiving fully suppressive antiretroviral regimens.

Original languageEnglish (US)
Pages (from-to)2614-2621
Number of pages8
JournalNew England Journal of Medicine
Volume356
Issue number25
DOIs
StatePublished - Jun 21 2007

Fingerprint

Virus Replication
Hepatitis B virus
HIV-1
Pharmaceutical Preparations
Coinfection
Lamivudine
Chronic Hepatitis B
Virus Diseases
United States Food and Drug Administration
entecavir
RNA
Mutation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

McMahon, M. A., Jilek, B. L., Brennan, T. P., Shen, L., Zhou, Y., Wind-Rotolo, M., ... Thio, C. L. (2007). The HBV drug entecavir - Effects on HIV-1 replication and resistance. New England Journal of Medicine, 356(25), 2614-2621. https://doi.org/10.1056/NEJMoa067710

The HBV drug entecavir - Effects on HIV-1 replication and resistance. / McMahon, Moira A.; Jilek, Benjamin L.; Brennan, Timothy P.; Shen, Lin; Zhou, Yan; Wind-Rotolo, Megan; Xing, Sifei; Bhat, Shridhar; Hale, Braden; Hegarty, Robert; Chong, Curtis R.; Liu, Jun; Siliciano, Robert F; Thio, Chloe L.

In: New England Journal of Medicine, Vol. 356, No. 25, 21.06.2007, p. 2614-2621.

Research output: Contribution to journalArticle

McMahon, MA, Jilek, BL, Brennan, TP, Shen, L, Zhou, Y, Wind-Rotolo, M, Xing, S, Bhat, S, Hale, B, Hegarty, R, Chong, CR, Liu, J, Siliciano, RF & Thio, CL 2007, 'The HBV drug entecavir - Effects on HIV-1 replication and resistance', New England Journal of Medicine, vol. 356, no. 25, pp. 2614-2621. https://doi.org/10.1056/NEJMoa067710
McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M et al. The HBV drug entecavir - Effects on HIV-1 replication and resistance. New England Journal of Medicine. 2007 Jun 21;356(25):2614-2621. https://doi.org/10.1056/NEJMoa067710
McMahon, Moira A. ; Jilek, Benjamin L. ; Brennan, Timothy P. ; Shen, Lin ; Zhou, Yan ; Wind-Rotolo, Megan ; Xing, Sifei ; Bhat, Shridhar ; Hale, Braden ; Hegarty, Robert ; Chong, Curtis R. ; Liu, Jun ; Siliciano, Robert F ; Thio, Chloe L. / The HBV drug entecavir - Effects on HIV-1 replication and resistance. In: New England Journal of Medicine. 2007 ; Vol. 356, No. 25. pp. 2614-2621.
@article{f312e3faa99842ee81224978a89ccc77,
title = "The HBV drug entecavir - Effects on HIV-1 replication and resistance",
abstract = "Entecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus type 1 (HIV-1) at clinically relevant doses. We observed that entecavir led to a consistent 1-log 10 decrease in HIV-1 RNA in three persons with HIV-1 and HBV coinfection, and we obtained supportive in vitro evidence that entecavir is a potent partial inhibitor of HIV-1 replication. Detailed analysis showed that in one of these patients, entecavir monotherapy led to an accumulation of HIV-1 variants with the lamivudine-resistant mutation, M184V. In vitro experiments showed that M184V confers resistance to entecavir. Until more is known about HIV-1-resistance patterns and their selection by entecavir, caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who are not receiving fully suppressive antiretroviral regimens.",
author = "McMahon, {Moira A.} and Jilek, {Benjamin L.} and Brennan, {Timothy P.} and Lin Shen and Yan Zhou and Megan Wind-Rotolo and Sifei Xing and Shridhar Bhat and Braden Hale and Robert Hegarty and Chong, {Curtis R.} and Jun Liu and Siliciano, {Robert F} and Thio, {Chloe L}",
year = "2007",
month = "6",
day = "21",
doi = "10.1056/NEJMoa067710",
language = "English (US)",
volume = "356",
pages = "2614--2621",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "25",

}

TY - JOUR

T1 - The HBV drug entecavir - Effects on HIV-1 replication and resistance

AU - McMahon, Moira A.

AU - Jilek, Benjamin L.

AU - Brennan, Timothy P.

AU - Shen, Lin

AU - Zhou, Yan

AU - Wind-Rotolo, Megan

AU - Xing, Sifei

AU - Bhat, Shridhar

AU - Hale, Braden

AU - Hegarty, Robert

AU - Chong, Curtis R.

AU - Liu, Jun

AU - Siliciano, Robert F

AU - Thio, Chloe L

PY - 2007/6/21

Y1 - 2007/6/21

N2 - Entecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus type 1 (HIV-1) at clinically relevant doses. We observed that entecavir led to a consistent 1-log 10 decrease in HIV-1 RNA in three persons with HIV-1 and HBV coinfection, and we obtained supportive in vitro evidence that entecavir is a potent partial inhibitor of HIV-1 replication. Detailed analysis showed that in one of these patients, entecavir monotherapy led to an accumulation of HIV-1 variants with the lamivudine-resistant mutation, M184V. In vitro experiments showed that M184V confers resistance to entecavir. Until more is known about HIV-1-resistance patterns and their selection by entecavir, caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who are not receiving fully suppressive antiretroviral regimens.

AB - Entecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus type 1 (HIV-1) at clinically relevant doses. We observed that entecavir led to a consistent 1-log 10 decrease in HIV-1 RNA in three persons with HIV-1 and HBV coinfection, and we obtained supportive in vitro evidence that entecavir is a potent partial inhibitor of HIV-1 replication. Detailed analysis showed that in one of these patients, entecavir monotherapy led to an accumulation of HIV-1 variants with the lamivudine-resistant mutation, M184V. In vitro experiments showed that M184V confers resistance to entecavir. Until more is known about HIV-1-resistance patterns and their selection by entecavir, caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who are not receiving fully suppressive antiretroviral regimens.

UR - http://www.scopus.com/inward/record.url?scp=34250722018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250722018&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa067710

DO - 10.1056/NEJMoa067710

M3 - Article

VL - 356

SP - 2614

EP - 2621

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 25

ER -